Immediate Impact
48 standout
Citing Papers
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
2024 Standout
Works of Huiqing Yu being referenced
OA01.08 A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+ Advanced or Recurrent NSCLC Patients
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Huiqing Yu | 84 | 87 | 48 | 74 | 30 | 276 | |
| Xiaobin Yuan | 49 | 53 | 80 | 59 | 29 | 287 | |
| Tai‐Ping Lee | 32 | 55 | 19 | 68 | 24 | 306 | |
| Jiajing Lin | 85 | 102 | 48 | 15 | 41 | 313 | |
| Hao Wang | 38 | 140 | 46 | 43 | 22 | 316 | |
| Sook Young Kim | 31 | 127 | 37 | 129 | 26 | 331 | |
| Yumin Ke | 52 | 136 | 28 | 19 | 25 | 285 | |
| Lingfeng Min | 65 | 121 | 97 | 27 | 24 | 311 | |
| Adam Goldman | 130 | 50 | 32 | 22 | 23 | 316 | |
| Shuli Zhou | 77 | 86 | 23 | 9 | 22 | 327 | |
| Ali Bukhari | 201 | 45 | 28 | 38 | 25 | 287 |
All Works
Login with ORCID to disown or claim papers
Loading papers...